98%
921
2 minutes
20
von Willebrand factor (VWF) plays a key role in normal hemostasis, and deficiencies of VWF lead to clinically significant bleeding. We sought to identify novel modifiers of VWF levels in endothelial colony-forming cells (ECFCs) using single-cell RNA sequencing (scRNA-seq). ECFCs were isolated from patients with low VWF levels (plasma VWF antigen levels between 30 and 50 IU/dL) and from healthy controls. Human umbilical vein endothelial cells were used as an additional control cell line. Cells were characterized for their Weibel Palade body (WPB) content and VWF release. scRNA-seq of all cell lines was performed to evaluate for gene expression heterogeneity and for candidate modifiers of VWF regulation. Candidate modifiers identified by scRNA-seq were further characterized with small-interfering RNA (siRNA) experiments to evaluate for effects on VWF. We observed that ECFCs derived from patients with low VWF demonstrated alterations in baseline WPB metrics and exhibit impaired VWF release. scRNA-seq analyses of these endothelial cells revealed overall decreased VWF transcription, mosaicism of VWF expression, and genes that are differentially expressed in low VWF ECFCs and control endothelial cells (control ECs). An siRNA screen of potential VWF modifiers provided further evidence of regulatory candidates, and 1 such candidate, FLI1, alters the transcriptional activity of VWF. In conclusion, ECFCs from individuals with low VWF demonstrate alterations in their baseline VWF packaging and release compared with control ECs. scRNA-seq revealed alterations in VWF transcription, and siRNA screening identified multiple candidate regulators of VWF.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8990376 | PMC |
http://dx.doi.org/10.1182/blood.2021010683 | DOI Listing |
Blood
September 2025
INSERM, Le Kremlin Bicêtre, France.
Von Willebrand disease (VWD)-type 1 is a bleeding disorder characterized by a quantitative deficiency of functional von Willebrand factor (VWF). We designed a novel bispecific nanobody, named KB-V13A12, that aims to increase endogenous VWF levels by bridging it to albumin. KB-V13A12 comprises two single-domain antibodies, one targeting VWF and one targeting albumin.
View Article and Find Full Text PDFInt J Lab Hematol
September 2025
Service d'Hématologie Biologique, Clermont-Ferrand, France.
Background: Preanalytical conditions, particularly centrifugation protocols, are critical for producing high-quality platelet-poor plasma in hemostasis testing. Centrifuge braking is debated due to its potential impact on platelet remixing.
Objectives: To evaluate the effect of centrifuge braking on residual platelet counts and a broad panel of hemostasis assays using both fresh and double-centrifuged plasma.
Clin Exp Hepatol
June 2025
Department of Clinical Pathology, National Liver Institute, Menoufia University, Shebin EL-Kom, Menoufia, Egypt.
Aim Of The Study: Portal vein thrombosis (PVT) is frequently observed in liver cirrhosis patients and correlates with the severity of the underlying liver disease. Thrombocytopenia and thrombocytopathy are signs of liver cirrhosis. A disruption in platelet function may have an impact on the development of thrombosis, considering that platelets are essential in the formation of thrombosis.
View Article and Find Full Text PDFBlood Adv
September 2025
University of Pittsburgh, Pittsburgh, Pennsylvania, United States.
Postpartum hemorrhage (PPH) affects up to 44% of women with von Willebrand disease (VWD) despite recombinant VWF (rVWF) treatment. As tranexamic acid (TXA) reduced PPH-related deaths in the WOMAN trial, we assessed whether TXA combined with rVWF versus rVWF alone prevents PPH in VWD. VWD-Woman, a phase 3, open-label, randomized pilot trial, enrolled pregnant women ≥18 years with VWD (VWF:RCo <0.
View Article and Find Full Text PDFPerioper Med (Lond)
September 2025
Department of Neurosurgery, Puren Hospital Affiliated to Wuhan University of Science and Technology Qingshan District, No. 1, Benxi Street, Wuhan Hubei Province, 430081, China.
Objective: This study aimed to investigate the efficacy of endovascular embolization in treating ruptured intracranial aneurysms (RIAs).
Methods: RIA patients (n = 89) were grouped according to different surgical methods. The control group (n = 42) received aneurysm clipping surgery, whereas the observation group (n = 47) received endovascular embolization.